Tanja Schmidt

Tanja Schmidt

Auto-generated profile, based on publicly available information

Tanja Schmidt

WHO Regional Office for Europe, Copenhagen, Denmark

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
FKFranka Klatte-Schulz
Franka Klatte-Schulz
TSTanja Schmidt
Tanja Schmidt
MUMelanie Uckert
Melanie Uckert
SSSven Scheffler
Sven Scheffler
UKUlrich Kalus
Ulrich Kalus
BWBritt Wildemann
Britt Wildemann
The poor healing potential of tendons is still a clinical problem, and the use of Platelet Rich Plasma (PRP) was hypothesized to stimulate healing. As the efficacy of PRPs remains unproven, platelet lysate (PL) could be an alternative with its main advantages of storage and characterization before use. Five different blood products were prepared from 16 male donors: human serum, two PRPs (Arthrex, (PRP-ACP); RegenLab (PRP-BCT)), platelet concentrate (apheresis, PC), and PL (freezing-thawing destruction of PC). Additionally, ten commercial allogenic PLs (AlloPL) from pooled donors were tested. The highest concentration of most growth factors was found in AlloPL, whereas the release of growth factors lasted longer in the other products. PRP-ACP, PRP-BCT, and PC significantly increased cell viability of human tenocyte-like cells, whereas PC and AlloPL increased Col1A1 expression and PRP-BCT increased Col3A1 expression. MMP-1, IL-1β, and HGF expression was significantly increased and Scleraxis expression decreased by most blood products. COX1 expression significantly decreased by PC and AlloPL. No clear positive effects on tendon cell biology could be shown, which might partially explain the weak outcome results in clinical practice. Pooled PL seemed to have the most beneficial effects and might be the future in using blood products for tendon tissue regeneration.

5 February 2012 in Cell and Tissue Banking
Verified
Journal Article
Closed access
PDF file
TSTanja Schmidt
Tanja Schmidt
AHArnd Hoburg
Arnd Hoburg
CBChristine Broziat
Christine Broziat
MSMark D. Smith
Mark D. Smith
UGUwe Gohs
Uwe Gohs
SSSven Scheffler
Sven Scheffler

4 February 2021 in Scientific Reports
Verified
Journal Article
Open access
PDF file
MRMarkus Reinthaler
Markus Reinthaler
JGJohannes Grosshauser
Johannes Grosshauser
TSTanja Schmidt
Tanja Schmidt
JUJuliane Unger
Juliane Unger
RMRoss Morgan
Ross Morgan
CSCarsten Skurk
Carsten Skurk
Left atrial appendage (LAA) closure is being developed as an alternative for stroke prevention in patients with atrial fibrillation that cannot tolerate long-term oral anticoagulation. To assess the feasibility, safety, and performance of a novel modified Occlutech LAA closure device in a preclinical porcine model, the modified Occlutech modified Occlutech Plus LAA closure device was implanted in 12 female pigs (25–39 kg body weight) under fluoroscopic and transesophageal echocardiography (TEE) guidance. Procedural and technical success, as well as safety of LAA closure, were evaluated peri-procedurally and after 4, 8, and 12 weeks. Moreover, after 4, 8 and, 12 weeks animals were sacrificed for pathological analysis (e.g., thrombus formation, device ingrowth, endothelialization, and inflammation). All LAA closure devices were successfully implanted. On follow-up, no serious adverse events such as device-associated thrombus or translocalization/embolization were observed. A clinically non-significant pericarditis was observed in 4 animals at the time of autopsy. Endothelialization of the device was visible after 4 weeks, advanced after 8 weeks and completed after 12 weeks. Immunohistochemistry showed low amounts of inflammatory infiltration on the edges of the device. The results of this study indicate that implantation of a modified Occlutech LAA closure device is feasible with rapid endothelialization and low inflammatory infiltration in a porcine model. Human data are needed to further characterize safety and efficacy.

21 May 2025 in Prehospital and Disaster Medicine
Verified
Journal Article
Open access
PDF file
RKRyoma Kayano
Ryoma Kayano
VMVirginia Murray
Virginia Murray
TSTanja Schmidt
Tanja Schmidt
DDDonald A Donahue
Donald A Donahue
PBPaul Barach
Paul Barach
JAJonathan Abrahams
Jonathan Abrahams
Background/Introduction: Disasters and emergencies cause devastating impacts on communities, infrastructure, economies, and health. Protecting health from emergencies and disasters are the goals in the WHO’s thirteenth and fourteenth General Program of Work (GPW 13 and GPW 14). Objectives: Build robust scientific evidence and support, facilitate, and celebrate reliable research to for informed decision-making and effective policy and practice. Method/Description: WHO established a global expert network in 2018, “WHO Thematic Platform for Health EDRM Research Network (Health EDRM RN)”. The WHO Centre for Health Development (WHO Kobe Centre (WKC)), the secretariat of the Health EDRM RN, facilitates international collaboration for better knowledge generation, synthesis, and dissemination. In 2021, in collaboration with 164 experts from WHO HQ, all Regional Offices, and 30 countries, WHO Guidance on Research Methods for Health EDRM (the Guidance) was developed, which provides concrete guidance on how to plan, conduct and report Health EDRM research. Results/Outcomes: The Health EDRM has promoted numerous training and policy meetings including (i) In 2023, a joint webinar by WHO Regional Office for Europe (EURO), WHO Regional Office for Eastern Mediterranean, and WKC;(ii) In 2024, a joint workshop for European countries and partners by WHO EURO and WKC with support of UK Health Security Agency; (iii) Symposiums and workshops in collaboration with academic societies including World Association of Disaster and Emergency Medicine, ASEAN Academic Conference, and Japanese Association for Disaster Medicine since 2021. Conclusion: WHO will continue to collate and improve scientific evidence that informs more effective and sustainable disaster and emergency policies and practices.